Targeted nanotherapy: a new frontier for TSCC treatment
en-GBde-DEes-ESfr-FR

Targeted nanotherapy: a new frontier for TSCC treatment

27/01/2025 TranSpread

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and treatment of tongue squamous cell carcinoma (TSCC). By harnessing gold nanoparticles coupled with the HN-1 peptide, this innovative system targets TSCC cells with unprecedented precision, offering enhanced photothermal therapy (PTT) and dual-mode imaging capabilities. With the ability to localize photosensitizers at tumor sites, the system boosts the effectiveness of tumor ablation, while its fluorescence and computed tomography (CT) imaging functions ensure accurate tumor detection and surgical margin identification. This breakthrough technology holds the potential to significantly improve treatment outcomes and the quality of life for patients battling TSCC.

Tongue squamous cell carcinoma (TSCC) is an aggressive cancer that is notoriously difficult to treat, with a high rate of metastasis and recurrence. Conventional therapies such as surgery, chemotherapy, and radiotherapy often lack the necessary specificity, resulting in debilitating side effects and diminished quality of life. Furthermore, accurately defining tumor margins during surgery remains a challenge, which can lead to incomplete resections and higher recurrence rates. With a grim prognosis and high mortality, TSCC underscores the urgent need for more effective, targeted therapies that can improve survival rates while minimizing collateral damage to healthy tissues.

Published (DOI: 10.1038/s41368-024-00343-7) on January 14, 2025, in the International Journal of Oral Science, researchers from Jilin University introduced the Au-HN-1 nanosystem, an innovative development designed for the dual purpose of targeting and treating TSCC. The study demonstrates how gold nanoparticles, modified with the HN-1 peptide, enable precise targeting of cancer cells, offering hope for more effective treatments for this deadly disease.

The Au-HN-1 nanosystem represents a quantum leap in the treatment and diagnosis of TSCC. By linking gold nanodots with the HN-1 peptide, the research team achieved highly selective targeting of TSCC cells, significantly improving the accumulation of photosensitizers at tumor sites. This targeted approach enhanced the efficacy of photothermal therapy (PTT) in mouse models, reducing tumor volumes without causing systemic toxicity. The nanosystem’s dual-mode imaging (fluorescence and CT) also allowed for accurate tumor localization and delineation of surgical margins—an essential factor in improving surgical outcomes. With its stability, biocompatibility, and minimal side effects, the Au-HN-1 system shows promising potential for long-term in vivo imaging and personalized cancer therapy. By combining diagnostic and therapeutic functions into a single, versatile system, this breakthrough minimizes damage to healthy tissues, marking a significant advance in cancer nanotechnology.

Dr. Guoqing Wang, the lead researcher of the study, emphasized the importance of this breakthrough: “The Au-HN-1 nanosystem is a major step forward in TSCC treatment, as it integrates targeted therapy with dual-mode imaging. This combination enhances therapeutic precision while safeguarding healthy tissue, pushing the boundaries of what’s possible in cancer nanotherapy.”

The Au-HN-1 nanosystem could transform the landscape of TSCC treatment and beyond. Its ability to improve photothermal therapy through targeted delivery of photosensitizers, coupled with real-time imaging, allows for precise tumor ablation and clearer tumor margin identification. This technology has the potential to revolutionize surgical procedures, reducing recurrence rates and improving patient outcomes. Furthermore, the versatility of the nanosystem suggests that it may be applicable to other head and neck cancers, offering hope for more effective and minimally invasive treatments. As ongoing research refines this system, it may pave the way for more personalized and precise cancer therapies, ultimately enhancing the lives of patients with TSCC and related malignancies.

###

References

DOI: 10.1038/s41368-024-00343-7

Original Url: https://doi.org/10.1038/s41368-024-00343-7

Founding information

This work was supported by the Science and Technology Projects of Jilin Provincial Department of Science and Technology (Grant/Award Numbers: 20240305037YY), National Key Research and Development Program of China (2021YFC2400603), the Joint Funds of the National Natural Science Foundation of China (Grant No. U23A20269), and the Jilin University young teachers and students cross-disciplinary training project (Grant No. 2023-JCXK-08, 2024-JCXK-07).

About International Journal of Oral Science

International Journal of Oral Science (ISSN 1674-2818) was founded in 2009 and aims to publish all aspects of oral science and interdisciplinary fields, including fundamental, applied and clinical research. Covered areas include oral microbiology, oral and maxillofacial oncology, cariology, oral inflammation and infection, dental stem cells and regenerative medicine, craniofacial surgery, dental materials, oral biomechanics, oral, dental and maxillofacial genetic and developmental diseases.

Paper title: Tongue squamous cell carcinoma-targeting Au-HN-1 nanosystem for CT imaging and photothermal therapy
DOI: 10.1038/s41368-024-00343-7
Attached files
  • Illustration of the synthesis of Au-HN-1 and its application in tumor site imaging and PTT therapy
27/01/2025 TranSpread
Regions: North America, United States, Asia, China
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement